Today's Rundown Featured Story | | | Tuesday, February 5, 2019 German Merck, already partnered up with Pfizer on their immuno-oncology drug Bavencio, is hitting up another Big Pharma for developmental work worth billions in biobucks for a next-generation I-O drug that can take on Keytruda. |
|
|
Top Stories Tuesday, February 5, 2019 Buried in among Gilead’s fourth-quarter results statement is a line revealing it has abandoned an anti-BCMA cell therapy for multiple myeloma, part of its $12 billion acquisition of Kite Pharma. Tuesday, February 5, 2019 A phase 3 trial of Sanofi’s Darzalex rival isatuximab in multiple myeloma has hit its primary endpoint. The anti-CD38 antibody prolonged progression-free survival over standard of care, providing a boost for Sanofi’s shift toward in-house programs. Tuesday, February 5, 2019 Decibel Therapeutics has brought on Peter Weber, M.D., as its new chief medical officer as the company plans to begin proof-of-concept and efficacy studies this year for its lead small molecule programs for hearing loss caused by drug toxicities. Tuesday, February 5, 2019 Taiho will grant an exclusive worldwide license—excluding Japan—to Cullinan’s new U.S. subsidiary in exchange for the usual upfront fee and potential milestones and royalties. Monday, February 4, 2019 The blood cancer-focused immunotherapy company Kiadis Pharma is bringing on Robert Friesen, Ph.D., to serve as its chief scientific officer. Monday, February 4, 2019 One of the reasons HIV infection is so hard to prevent and treat is that the virus mutates in order to evade broadly neutralizing antibodies—the immune system’s primary defense against viral pathogens. So scientists at the Fred Hutchinson Cancer Research Center constructed an atlas of HIV mutations, providing insight that they believe will boost the ongoing search for an effective vaccine. | This week's sponsor is Camargo. | |  | [Webinar] Maximizing the Value of Your Drug Development Program
Thursday, February 21 | 11am ET / 8am PT
This webinar will benefit executives at Biotech and Pharmaceutical companies interested in learning more about 505(b)(2) drug development and how to save time and money while maximizing the value of their drug development program. Register Now! |
Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|
Resources Sponsored by: Patheon, part of Thermo Fisher Scientific When a biologics company prepares to launch a new product, it must forecast the manufacturing capacity it will need, factoring in its estimate of the size of future sales, the timing of the launch, the dosage of the product, its strategy for building its market and a host of other variables. Sponsored by: Oracle Health Sciences 92% of survey respondents make changes to their RTSM/IRT systems due to study changes. See what else puts a strain on their clinical trials. Download the Research Whitepaper. Sponsored by: Patheon, part of Thermo Fisher Scientific Download this whitepaper to learn more. Sponsored by: The Kinetix Group Explore how the pharma industry can adapt its approach to the changing healthcare marketplace in the era of the Quadruple Aim Sponsored by: Cofactor Genomics Learn how Health Expression Models provide increased sensitivity, specificity, and accuracy for characterizing immune response in solid tumor specimens. Sponsored by: BioAnalytix, Inc. This whitepaper reviews fundamental aspects of HCPs that pertain to biologic drug development and presents current and emerging approaches to HCP analysis. Sponsored by: Veradigm Clinical trials take too long and cost too much—here's what needs to change. Sponsored by: AlphaSense It’s never been more challenging to stay on top of competitive factors impacting your industry. Discover how AI can help competitive teams achieve more proactive market intelligence. Sponsored by: Reprints Desk, Inc. Go from Search to Full-Text Scientific Papers in a Single Click! Sponsored by: Blue Latitude Health This white paper consists of original data and expert interviews. Download it today for exclusive tools, tips and analysis on achieving launch excellence in challenging pharma markets. Sponsored by: Outer Edge Technology With FDA approval imminent, start-up Life Sciences company partners with an industry focused MSP to design and manage its regulated cloud-based infrastructure to speed time to market. Sponsored by: DeciBio Consulting With the liquid biopsy market maturing and >80 companies still competing with liquid biopsy offerings, it is crucial for investors to be able to cut through the noise and identify the winners. Presented by: Veeva Share your thoughts on the life sciences industry's progress in improving study execution. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 
